ERBB2 and breast cancer: Although HER4 has been shown to have an anti-proliferative activity in breast cancer cells [8-10], we showed that HER4 silencing decreased cell viability and enhanced trastuzumab effect as well as reversed its resistance in HER2 positive breast cancer cells.